Related references
Note: Only part of the references are listed.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
F. Anthony Romero et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation
Xue-Jing Liu et al.
LIVER INTERNATIONAL (2020)
New drugs for non-alcoholic steatohepatitis
Ana-Carolina Cardoso et al.
LIVER INTERNATIONAL (2020)
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Margaret M. Billingsley et al.
NANO LETTERS (2020)
Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities
Jinfang Zhang et al.
ACS NANO (2020)
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Jean-Francois Dufour et al.
GUT (2020)
Nonalcoholic Steatohepatitis: A Review
Adam C. Sheka et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH
Fang Xu et al.
REDOX BIOLOGY (2020)
End-points for drug treatment in NASH
Leon A. Adams
HEPATOLOGY INTERNATIONAL (2019)
Resolving inflammation in nonalcoholic steatohepatitis
Matthew Spite
JOURNAL OF CLINICAL INVESTIGATION (2019)
A maresin 1/RORα/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis
Yong-Hyun Han et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Konstantin Kazankov et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akin Akinc et al.
NATURE NANOTECHNOLOGY (2019)
Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases
Daphne van der Heide et al.
FRONTIERS IN IMMUNOLOGY (2019)
Current and future pharmacological therapies for NAFLD/NASH
Yoshio Sumida et al.
JOURNAL OF GASTROENTEROLOGY (2018)
pPB Peptide-Mediated siRNA-Loaded Stable Nucleic Acid Lipid Nanoparticles on Targeting Therapy of Hepatic Fibrosis
Zongxiang Jia et al.
MOLECULAR PHARMACEUTICS (2018)
HMGB1-induced autophagy facilitates hepatic stellate cells activation: a new pathway in liver fibrosis
Jing Li et al.
CLINICAL SCIENCE (2018)
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
Oliver Krenkel et al.
HEPATOLOGY (2018)
Pharmacotherapy for NASH: Current and emerging
Monica A. Konerman et al.
JOURNAL OF HEPATOLOGY (2018)
Triggering and resolution of inflammation in NASH
Susanne Schuster et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting hepatic macrophages to treat liver diseases
Frank Tacke
JOURNAL OF HEPATOLOGY (2017)
Therapies in non-alcoholic steatohepatitis (NASH)
Abdul M. Oseini et al.
LIVER INTERNATIONAL (2017)
Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments
Hironori Kitade et al.
NUTRIENTS (2017)
RORα Induces KLF4-Mediated M2 Polarization in the Liver Macrophages that Protect against Nonalcoholic Steatohepatitis
Yong-Hyun Han et al.
CELL REPORTS (2017)
Targeting distinct myeloid cell populations in vivo using polymers, liposomes and microbubbles
Can Ergen et al.
BIOMATERIALS (2017)
Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood
Sonya A. MacParland et al.
ACS NANO (2017)
Perspectives on Treatment for Nonalcoholic Steatohepatitis
Guillaume Lassailly et al.
GASTROENTEROLOGY (2016)
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Amon Asgharpour et al.
JOURNAL OF HEPATOLOGY (2016)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
Herbert Tilg et al.
HEPATOLOGY (2010)
Rational design of cationic lipids for siRNA delivery
Sean C. Semple et al.
NATURE BIOTECHNOLOGY (2010)
The Plasma Lipidomic Signature of Nonalcoholic Steatohepatitis
Puneet Puri et al.
HEPATOLOGY (2009)
A lipidomic analysis of nonalcoholic fatty liver disease
Puneet Puri et al.
HEPATOLOGY (2007)
Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease
LA Videla et al.
FREE RADICAL BIOLOGY AND MEDICINE (2004)
Pharmacokinetics of pegylated liposomal doxorubicin - Review of animal and human studies
A Gabizon et al.
CLINICAL PHARMACOKINETICS (2003)
Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats
BN Melgert et al.
HEPATOLOGY (2001)
Share Paper
